HighLife Medical is a structural heart company and has developed a system to replace mitral valves via a trans-apical or trans-septal approach.
Location: France, Ile-de-France
Employees: 11-50
Total raised: $50.8M
Founded date: 2010
Investors 4
| Date | Name | Website |
| - | US Venture... | usvp.com |
| - | Sofinnova ... | sofinnovap... |
| - | Andera Par... | anderapart... |
| - | VI Partner... | vipartners... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.01.2019 | Series B | $36.47M | - |
| 30.10.2017 | - | $14.33M | - |
Mentions in press and media 11
| Date | Title | Description |
| 25.07.2024 | Andera Partners’ portfolio company JenaValve Technology acquired by Edwards Lifesciences | Andera Partners, a leading European private equity player, announced today that its portfolio company, JenaValve Technology, a pioneer in the transcatheter treatment of aortic regurgitation (AR), will be acquired by Edwards Lifesciences, a ... |
| 21.12.2020 | Significant agreements with Chinese market leaders in our Life Sciences portfolio | Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China • Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensi... |
| 01.02.2019 | 10 notable European tech startups that got maximum funding in January 2019 | The European tech scene is a thriving community for the startups and aspiring entrepreneurs. Several European countries are becoming the most capable places for startups. With the favourable business environment in many of these countries, ... |
| 22.01.2019 | French health tech startup HighLife closes a €32M round B financing | With every passing day, the number of cardiac patients are escalating globally. Mitral regurgitation is one of such serious heart ailments that take thousands of lives every year. As per expert reports, over 4 million patients are suffering... |
| 18.01.2019 | Paris-based HighLife raises €32 million Series B for its device to treat heart disease | Paris-based HighLife SAS is a medtech company developing a treatment for patients suffering from mitral regurgitation – a serious heart condition in which blood leaks backwards through the mitral valve each time the left ventricle contracts... |
| 18.01.2019 | Daily funding roundup - January 18th, 2019 | Vinebox raised $5.9M; HyperScience raised $30M; Limelight Health raised $33.5M SimplyCook: SimplyCook offers home recipe kits with easy step-by-step guides to cook restaurant quality food in less than 20 minutes. SimplyCook has raised £4.5 ... |
| 18.01.2019 | Term Sheet — Friday, January 18 | WALL STREET’S UNLIKELY STAR Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop In its fourth quarter report, it reported the highest earnings in company history. The bank posted a $8.7 billion i... |
| 18.01.2019 | HighLife Closes €32M Series B Financing Round | HighLife SAS, a Paris, France-based medtech company focused on the development of a transcatheter mitral valve replacement (“TMVR”) system to treat patients suffering from mitral regurgitation, closed a €32m Series B equity financing round.... |
| 17.01.2019 | HighLife raises $36m Series B for mitral valve replacement | - |
| 31.10.2017 | Term Sheet — Tuesday, October 31 | DEAD AND GONE Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop The top 5 in the startup graveyard (ranked by valuation): JAWBONE A developer of wearable tech and portable audio devices. Va... |
Show more